- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 clinical trials, Lumvoa...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced...
- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready - - Marketing Authorization Application (MAA) for...
Barchart Research What to Expect from VRDN Earnings VRDN Generated May 4, 2026 Current Price $14.06 EPS Estimate $$-1.05 Consensus Rating Strong Buy Average Move 4.70% Viridian's Clinical Win Already Priced...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.78%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.18%. Stock indexes turned lower...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.42%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. June E-mini S&P futures (ESM26...
- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved...